miR‑378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβ and c‑Raf

Fu,Hongxia; Zhang,Jicai; Pan,Tongshan; Ai,Shuying; Tang,Li; Wang,Fengqin

doi:10.3892/mmr.2018.8390

miR‑378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβ and c‑Raf

Authors:
- Hongxia Fu
- Jicai Zhang
- Tongshan Pan
- Shuying Ai
- Li Tang
- Fengqin Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Pediatrics, Danjiangkou First Hospital, Danjiangkou, Hubei 442700, P.R. China, Department of Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Neurology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: January 8, 2018 https://doi.org/10.3892/mmr.2018.8390
Pages: 4581-4588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is a globally prevalent cancer with poor prognosis. The present study investigated the link between microRNA-378a (miR‑378a) expression and the sensitivity of hepatocellular carcinoma (HCC) and hepatoblastoma (HB) cancers to sorafenib therapy. miR‑378a expression was determined in liver tissue samples from healthy candidates and patients with liver cancer using the reverse transcription‑quantitative polymerase chain reaction. The antitumor effects of miR‑378a alone and in combination with sorafenib were investigated in the HB cell line HepG2 and the HCC cell line SMMC‑7721 with methyl thiazoyl tetrazolium, colony formation, flow cytometry and Transwell migration assays. The underlying mechanisms were investigated using western blot analysis. miR‑378a expression was decreased in tissue samples from patients with liver cancer. HCC and HB cell line proliferation and invasion ability was inhibited by miR‑378a. The combination of miR‑378a and sorafenib provided the greatest inhibition. Western blot indicated that mitogen activated protein kinase signaling pathway proteins, vascular endothelial growth factor receptor, platelet derived growth factor receptor β, Raf‑1 proto‑oncogene, serine/threonine kinase and matrix metallopeptidase 2 were regulated by miR‑378a alone and to a greater extent when combined with sorafenib. Results suggest that miR‑378a can inhibit liver cancer cell growth and enhance the sensitivity of liver cancer cells to sorafenib‑based chemotherapies.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global Cancer Statistics, 2012. Ca Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC and Zdeb MS: Maternal and infant birth characteristics and hepatoblastoma. Am J Epidemiol. 163:818–828. 2006. View Article : Google Scholar : PubMed/NCBI
4	Trobaugh-Lotrario AD, Meyers RL, O'Neill AF and Feusner JH: Unresectable hepatoblastoma: Current perspectives. Hepatic Med. 9:1–6. 2017. View Article : Google Scholar
5	Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg. 100:22–29. 2011. View Article : Google Scholar : PubMed/NCBI
6	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
7	Rodríguez-Hernández A, Navarro-Villarán E, González R, Pereira S, Soriano-De Castro LB, Sarrias-Giménez A, Barrera-Pulido L, Álamo-Martínez JM, Serrablo-Requejo A, Blanco-Fernández G, et al: Regulation of cell death receptor S-nitrosylation and apoptotic signaling by sorafenib in hepatoblastoma cells. Redox Biology. 6:174–182. 2015. View Article : Google Scholar : PubMed/NCBI
8	Shanmugam N, Valamparampil JJ, Scott JX, Vij M, Narasimhan G, Reddy MS and Rela M: Complete remission of refractory hepatoblastoma after liver transplantation in a child with sorafenib monotherapy: A new hope? Pediatric Blood Cancer. Jul 17–2017.(Epub ahead of print). View Article : Google Scholar
9	Dazert E..Colombi M, Boldanova T, Moes S, Adametz D, Quagliata L, Roth V, Terracciano L, Heim MH, Jenoe P and Hall MN: Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proc Natl Acad Sci USA. 113:pp. 1381–1386. 2016; View Article : Google Scholar : PubMed/NCBI
10	Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT and Gedaly R: Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res. 34:1709–1713. 2014.PubMed/NCBI
11	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
12	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
13	Song X, Wang Z, Jin Y, Wang Y and Duan W: Loss of miR-532-5p in vitro promotes cell proliferation and metastasis by influencing CXCL2 expression in HCC. Am J Transl Res. 7:2254–2261. 2015.PubMed/NCBI
14	Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, Li Q, Zhang Y, Ding Y, Chen B and Chen L: MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 9:e883932014. View Article : Google Scholar : PubMed/NCBI
15	Gao B, Gao K, Li L, Huang Z and Lin L: miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomed Pharmacother. 68:143–148. 2014. View Article : Google Scholar : PubMed/NCBI
16	He J, Guo X, Sun L, Wang N and Bao J: Regulatory network analysis of genes and microRNAs in human hepatoblastoma. Oncol Lett. 12:4099–4106. 2016. View Article : Google Scholar : PubMed/NCBI
17	Cairo S, Wang Y, de Reyniès A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM and Buendia MA: Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci USA. 107:pp. 20471–20476. 2010; View Article : Google Scholar : PubMed/NCBI
18	Chen QG, Zhou W, Han T, Du SQ, Li ZH, Zhang Z, Shan GY and Kong CZ: miR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo. Tumor Biol. 37:2095–2103. 2016. View Article : Google Scholar
19	Wei X, Li H, Zhang B, Li C, Dong D, Lan X, Huang Y, Bai Y, Lin F, Zhao X and Chen H: miR-378a-3p promotes differentiation and inhibits proliferation of myoblasts by targeting HDAC4 in skeletal muscle development. RNA Biol. 13:1300–1309. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Li C, Li H, Song Y, Zhao Y, Zhai L, Wang H, Zhong R, Tang H and Zhu D: miR-378 activates the pyruvate-pep futile cycle and enhances lipolysis to ameliorate obesity in mice. EBioMedicine. 5:93–104. 2016. View Article : Google Scholar : PubMed/NCBI
21	International Union Against Cancer (UICC), . TNM classification of malignant tumors. Sobin LH, Gospodarowicz MK and Wittekind Ch: 7th. Wiley-Blackwell; Oxford: 2010
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Khare S, Zhang Q and Ibdah JA: Epigenetics of hepatocellular carcinoma: Role of microRNA. World J Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI
24	Nakao K, Miyaaki H and Ichikawa T: Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhu H, Wang G, Zhou X, Song X, Gao H, Ma C, Chang H, Li H, Liu FF, Lu J and Ma J: miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6. Biomed Pharmacother. 83:792–797. 2016. View Article : Google Scholar : PubMed/NCBI
26	Huang CY, Huang XP, Zhu JY, Chen ZG, Li XJ, Zhang XH, Huang S, He JB, Lian F, Zhao YN and Wu GB: miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients. Oncol Rep. 33:2889–2898. 2015. View Article : Google Scholar : PubMed/NCBI
27	Chang L, Li K and Guo T: miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC. Clin Transl Oncol. 19:695–703. 2016. View Article : Google Scholar : PubMed/NCBI
28	Krist B, Florczyk U, Pietraszek-Gremplewicz K, Józkowicz A and Dulak J: The role of miR-378a in metabolism, angiogenesis, and muscle biology. Int J Endocrinol. 2015:2817562015. View Article : Google Scholar : PubMed/NCBI
29	Huang N, Wang J, Xie W, Lyu Q, Wu J, He J, Qiu W, Xu N and Zhang Y: miR-378a-3p enhances adipogenesis by targeting mitogen-activated protein kinase 1. Biochem Biophys Res Commun. 457:37–42. 2015. View Article : Google Scholar : PubMed/NCBI
30	Li H, Dai S, Zhen T, Shi H, Zhang F, Yang Y, Kang L, Liang Y and Han A: Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur J Cancer. 50:1207–1221. 2014. View Article : Google Scholar : PubMed/NCBI
31	Megiorni F, Cialfi S, McDowell HP, Felsani A, Camero S, Guffanti A, Pizer B, Clerico A, De Grazia A, Pizzuti A, et al: Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. BMC Cancer. 14:8802014. View Article : Google Scholar : PubMed/NCBI
32	Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H and Inoue S: miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 5:131702015. View Article : Google Scholar : PubMed/NCBI
33	Li C, Li Y, Lv H, Li S, Tang K, Zhou W, Yu S and Chen X: The novel anti-neuroblastoma agent PF403, inhibits proliferation and invasion in vitro and in brain xenografts. Int J Oncol. 47:179–187. 2015. View Article : Google Scholar : PubMed/NCBI
34	Gao J, Liu X, Yang F, Liu T, Yan Q and Yang X: By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Oncotarget. 6:27187–27198. 2015. View Article : Google Scholar : PubMed/NCBI
35	Moreno L, Popov S, Jury A, Al Sarraj S, Jones C and Zacharoulis S: Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma. J Neurooncol. 111:169–176. 2013. View Article : Google Scholar : PubMed/NCBI
36	Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL and Chung GG: High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol. 39:1835–1843. 2008. View Article : Google Scholar : PubMed/NCBI
37	Burotto M, Chiou VL, Lee JM and Kohn EC: The MAPK pathway across different malignancies: A new perspective. Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
38	Song X, Wei Z and Shaikh ZA: Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells. Toxicol Appl Pharmacol. 287:26–34. 2015. View Article : Google Scholar : PubMed/NCBI